Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Corren (Los Angeles, CA, United States of America), M. Liu (Baltimore, MD, United States of America), K. Bowen (Gaithersburg, MD, United States of America), K. Salapa (Warsaw, Poland), G. Colice (Gaithersburg, MD, United States of America), J. Llanos-Ackert (Thousand Oaks, CA, United States of America). Efficacy of tezepelumab in patients with low and high bronchodilator reversibility in PATHWAY. 2269

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Comparison of efficacy and safety of Obucort Swinghaler with Pulmicot Turbuhaler in mild to moderate severe asthma patients Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 Efficacy, safety and acceptance of salbutamol administered via MAGhaler in children with mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 430s Year: 2002 Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Low adherence to inhaled corticosteroids/long-acting ß2-agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001 Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Bronchodilator efficacy of tiotropium in patients with mild COPD Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 Variability in asthma severity among steroid-naive patients previously receiving short-acting beta2-agonists Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003 Efficacy of low dose theophylline in patient with bronchial asthma - anti-inflammatory effect Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003 Cardiovascular safety of high doses of the nebulized bronchodilators in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004 Indacaterol once-daily provides significant bronchodilation irrespective of baseline reversibility in COPD patients Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Analysis of bronchodilator response in patients with controlled asthma Source: Eur Respir J 2004; 24: Suppl. 48, 223s Year: 2004 Tolerability of high cumulative doses of a new fixed combination of beclomethasone dipropionate/formoterol in asthmatic patients Source: Eur Respir J 2006; 28: Suppl. 50, 316s Year: 2006 Comparative safety-efficacy trial using three inhaler combinations in moderate persistent asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006